CG MedTech Co., Ltd. (056090) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for CG MedTech Co., Ltd. (056090:KRX), powered by AI.
- Current Price
- ₩1,258
- P/E Ratio
- 20.0
- Market Cap
- 129.9B
- Sector
- Healthcare
What is the CG MedTech Co., Ltd. stock price forecast?
CG MedTech Co., Ltd. is currently trading at ₩1,258. View real-time AI analysis on Alpha Lenz.
What is CG MedTech Co., Ltd. insider trading activity?
View the latest insider trading data for CG MedTech Co., Ltd. on Alpha Lenz.
What is CG MedTech Co., Ltd.'s P/E ratio?
CG MedTech Co., Ltd.'s P/E ratio is 20.0.
CG MedTech Co., Ltd.
KRX · 056090“CG MedTech Co., Ltd. trades at a P/E of 20.0 (fair value) with modest ROE of 7.2%.”
Ask for details →Company Overview
CG MedTech Co., Ltd. is a prominent player in the healthcare industry, specializing in the development and production of medical devices and health care solutions. The company focuses on innovation and technological advancement to improve patient outcomes and streamline medical procedures. CG MedTech serves a variety of sectors within the healthcare space, providing products that cater to hospitals, clinics, and specialized medical facilities. It is known for its contributions to advancements in diagnostic equipment, as well as therapeutic devices that enhance medical care efficiency and effectiveness. This entity plays a significant role in the global medical technology market, influencing how modern healthcare practices are implemented and evolving the standards of patient care.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“CG MedTech Co., Ltd. trades at a P/E of 20.0 (fair value) with modest ROE of 7.2%.”
Ask for details →Frequently Asked Questions
CG MedTech Co., Ltd. (ticker: 056090) is a company listed on KRX in the Healthcare sector (Medical Devices). It has approximately 105 employees. Market cap is $129.9B.
The current price is ₩1,258 with a P/E ratio of 19.96x and P/B of 1.38x.
ROE is 7.18% and operating margin is 8.08%. Annual revenue is $47.2B.